stoxline Quote Chart Rank Option Currency Glossary
  
Seelos Therapeutics, Inc. (SEEL)
0.591  -0.048 (-7.56%)    03-28 16:00
Open: 0.65
High: 0.68
Volume: 443,175
  
Pre. Close: 0.6393
Low: 0.575
Market Cap: 8(M)
Technical analysis
2024-03-28 4:54:11 PM
Short term     
Mid term     
Targets 6-month :  1.14 1-year :  1.58
Resists First :  0.98 Second :  1.36
Pivot price 0.79
Supports First :  0.37 Second :  0.3
MAs MA(5) :  0.55 MA(20) :  0.88
MA(100) :  1.66 MA(250) :  16.47
MACD MACD :  -0.2 Signal :  -0.2
%K %D K(14,3) :  23.9 D(3) :  19.9
RSI RSI(14): 35.5
52-week High :  49.79 Low :  0.37
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SEEL ] has closed above bottom band by 30.8%. Bollinger Bands are 24.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.68 - 0.68 0.68 - 0.69
Low: 0.57 - 0.57 0.57 - 0.57
Close: 0.59 - 0.59 0.59 - 0.6
Company Description

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

Headline News

Tue, 19 Mar 2024
CNS Disorder-Focused Seelos Therapeutics Plunges To 52-Week Low - Here's Why - TradingView

Tue, 19 Mar 2024
Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS ... - PR Newswire

Tue, 19 Mar 2024
Seelos Therapeutics' ALS treatment fails mid-stage study - Reuters

Mon, 11 Mar 2024
Is Seelos Therapeutics Inc (SEEL) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Fri, 08 Mar 2024
Should You Buy Seelos Therapeutics Inc (SEEL) Stock After it Is Down 3.23% in a Week? - InvestorsObserver

Fri, 26 Jan 2024
Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 14 (M)
Held by Insiders 1.34e+007 (%)
Held by Institutions 2 (%)
Shares Short 409 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 226.8 %
Return on Equity (ttm) -179.8 %
Qtrly Rev. Growth 2.2e+006 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth -7.8 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -24 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -0.35
Stock Dividends
Dividend 0
Forward Dividend 292950
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android